FdaApplication
NDA 202022
Identifiers
- fda_app_no: NDA202022
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PRODUCTS LP |
| application_type | NDA |
| approval_date | 2011-05-20 |
Revenue by product
EDURANT
| Period | Revenue |
|---|---|
| Q2 2026 | $350.0M |
| Q1 2026 | $409.0M |
| Q4 2025 | $383.0M |
| Q3 2025 | $385.0M |
| Q2 2025 | $360.0M |
| Q1 2025 | $358.0M |
| Q4 2024 | $322.0M |
| Q3 2024 | $330.0M |
| Q2 2024 | $297.0M |
| Q1 2024 | $323.0M |
| Q4 2023 | $307.0M |
| Q3 2023 | $297.0M |
| Q2 2023 | $266.0M |
| Q1 2023 | $280.0M |
| Q4 2022 | $290.0M |
| Q3 2022 | $245.0M |
| Q2 2022 | $225.0M |
| Q1 2022 | $248.0M |
| Q4 2021 | $230.0M |
| Q3 2021 | $259.0M |
| Q2 2021 | $262.0M |
| Q1 2021 | $243.0M |
| Q4 2020 | $248.0M |
| Q3 2020 | $236.0M |
| Q2 2020 | $256.0M |
| Q1 2020 | $224.0M |
| Q4 2019 | $222.0M |
| Q3 2019 | $218.0M |
| Q2 2019 | $210.0M |
| Q1 2019 | $211.0M |
| Q4 2018 | $193.0M |
| Q3 2018 | $202.0M |
| Q2 2018 | $211.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EDURANT | RILPIVIRINE HYDROCHLORIDE | EQ 25MG BASE | TABLET;ORAL |
1 product